GoldCoast Resource Corp. (CNSX: GCR)
Health Care · Biotechnology · CA
CA$0.85
0.00% today · -21.2% 1Y
GoldCoast Resource Corp. (CNSX: GCR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $42.76M.
Over the last twelve months the share price has lost 21.2%, trading between 0.77 and 1.20.
GCR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.76M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.45
- Dividend yield
- —
- Beta (5Y)
- 1.31
- 52-week high
- CA$1.20
- 52-week low
- CA$0.77
- Avg volume (3M)
- —
- Shares outstanding
- 69.81M
- Employees
- —
- Next earnings
- —
About GoldCoast Resource Corp.
Psyence Group Inc. is a life sciences biotechnology company primarily engaged in the commercial cultivation and production of psilocybin mushrooms. This naturally sourced psilocybin is intended for therapeutic applications, addressing a broad spectrum of mental health conditions and other medical ailments. The company is actively formulating pharmaceutical-grade psilocybin treatments designed to mitigate psychological trauma and recognized disorders such as anxiety, depression, post-traumatic stress disorder (PTSD), and the emotional distress linked to grief and bereavement. Furthermore, Psyence Group develops, distributes, and sells over-the-counter functional mushroom nutraceuticals, entirely free of psilocybin, under its GOODMIND brand. Established in 2019, the company maintains its headquarters in Toronto, Canada.
- ISIN
- CA38077K1030
- Listed since
- Jan 27, 2021
- Exchange
- Canadian National Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.